Jean-Pierre has over 30 years of scientific, operational, strategic and management experience in the biotech industry. Previously Jean-Pierre was the Principal Founder of Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) and a Co-Founder of Pharmasset, Inc. (NASDAQ: VRUS). Both of these companies were acquired; Idenix by Merck for $3.85 billion in 2014 and Pharmasset by Gilead for $11 billion in 2012. Jean-Pierre held a number of key executive positions at Idenix, including Chairman of the Board of Directors, Executive President and Chief Scientific Officer from 1998 to 2000, and then as Chairman and Chief Executive Officer from 2000 to 2010. Under his leadership, Idenix entered into multiple strategic collaborations, including those with Sumitomo and GlaxoSmithKline (GSK) as well as a landmark biotech-pharma transaction with Novartis Pharma AG in 2003. During Jean-Pierre’s tenure, Idenix discovered, co-developed and co-launched telbuvidine (Tyzeka™/Sebivo®) for the treatment of hepatitis B, and established a major clinical pipeline of antiviral therapeutics for the treatment of hepatitis C and HIV/AIDS.
Jean-Pierre is Chairman of PegaOne, Chairman of Panchrest, Inc., and a member of the Board of The BioExec Institute, as well.
Prior to his entrepreneurial career, Jean-Pierre was on the faculty of the University of Alabama at Birmingham School of Medicine since March 1985. Jean-Pierre served as a Professor of Pharmacology, Toxicology and Clinical Pharmacology from June 1992 to November 2000. He has authored over 180 peer-reviewed publications and holds more than 60 U.S. patents associated with cancer and antiviral therapeutics.
Jean-Pierre holds a PharmD and PhD in Pharmacology from the University of Marseilles, France and was a post-doctoral Fogarty fellow at the National Cancer Institute and the Medical College of Virginia, and is a recipient of a Faculty Award from The American Cancer Society.
What is Jean-Pierre Sommadossi's net worth?
The estimated net worth of Jean-Pierre Sommadossi is at least $18.13 million as of September 19th, 2024. Sommadossi owns 5,866,025 shares of Atea Pharmaceuticals stock worth more than $18,126,017 as of December 5th. This net worth approximation does not reflect any other assets that Sommadossi may own. Additionally, Sommadossi receives a salary of $1,040,000.00 as CEO at Atea Pharmaceuticals. Learn More about Jean-Pierre Sommadossi's net worth.
How old is Jean-Pierre Sommadossi?
What is Jean-Pierre Sommadossi's salary?
How do I contact Jean-Pierre Sommadossi?
Has Jean-Pierre Sommadossi been buying or selling shares of Atea Pharmaceuticals?
Jean-Pierre Sommadossi has not been actively trading shares of Atea Pharmaceuticals during the last ninety days. Most recently, Jean-Pierre Sommadossi sold 1,841 shares of the business's stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $4.00, for a transaction totalling $7,364.00. Following the completion of the sale, the chief executive officer now directly owns 5,866,025 shares of the company's stock, valued at $23,464,100. Learn More on Jean-Pierre Sommadossi's trading history.
Who are Atea Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Atea Pharmaceuticals?
During the last twelve months, insiders at the sold shares 1 times. They sold a total of 359,606 shares worth more than $1,024,877.10. The most recent insider tranaction occured on December, 10th when Director Franklin M Berger sold 359,606 shares worth more than $1,024,877.10. Insiders at Atea Pharmaceuticals own 18.1% of the company.
Learn More about insider trades at Atea Pharmaceuticals. Information on this page was last updated on 12/10/2024.
